A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers

NCT02728830 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Gynecologic Neoplasms
Epithelial Ovarian Cancer
Uterine Endometrial Cancer
Fallopian Tube Cancer
Peritoneal Cancer

Interventions

DRUG: Pembrolizumab

Sponsor

AA Secord

Collaborators

[object Object]